Members of the VEGF family, which includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E, as well as placental growth factors, have been shown to increase vascular permeability, accelerate vascular endothelial cell migration and proliferation, and promote angiogenesis (Ferrara and Adamis, 2016), and VEGF and its signaling pathway are considered the optimal targets for anti-angiogenic and anti-tumor therapies for a variety of cancers (Potente et al., 2011; Gao et al., 2020). The gene discussed is VEGFA; the disease is cancer.